These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12799025)

  • 1. Dynamics of immune cell trafficking in interferon-beta treated multiple sclerosis patients.
    Hartrich L; Weinstock-Guttman B; Hall D; Badgett D; Baier M; Patrick K; Feichter J; Hong J; Ramanathan M
    J Neuroimmunol; 2003 Jun; 139(1-2):84-92. PubMed ID: 12799025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte subpopulations, oxidative burst and apoptosis in peripheral blood cells of patients with multiple sclerosis-effect of interferon-beta.
    Mix E; Stefan K; Höppner J; Klauer T; Zettl UK; Strauss U; Meyer-Rienecker HJ; Rolfs A
    Autoimmunity; 2003 Aug; 36(5):291-305. PubMed ID: 14567559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.
    Kastrukoff LF; Morgan NG; Zecchini D; White R; Petkau AJ; Satoh J; Paty DW
    Neurology; 1999 Jan; 52(2):351-9. PubMed ID: 9932956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon-beta.
    Lande R; Gafa V; Serafini B; Giacomini E; Visconti A; Remoli ME; Severa M; Parmentier M; Ristori G; Salvetti M; Aloisi F; Coccia EM
    J Neuropathol Exp Neurol; 2008 May; 67(5):388-401. PubMed ID: 18431257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins as immunomodulators: comparison with interferon-beta 1b in MS.
    Neuhaus O; Strasser-Fuchs S; Fazekas F; Kieseier BC; Niederwieser G; Hartung HP; Archelos JJ
    Neurology; 2002 Oct; 59(7):990-7. PubMed ID: 12370451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of interferon beta-1a on B7.1 and B7.2 B-cell expression and its impact on T-cell proliferation.
    Huang H; Ito K; Dangond F; Dhib-Jalbut S
    J Neuroimmunol; 2013 May; 258(1-2):27-31. PubMed ID: 23489746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of survivin expression in T lymphocytes after interferon beta-1a treatment in patients with multiple sclerosis.
    Sharief MK; Semra YK
    Arch Neurol; 2002 Jul; 59(7):1115-21. PubMed ID: 12117359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotyping analysis of peripheral blood leukocytes in patients with multiple sclerosis.
    Paź A; Fiszer U; Zaborski J; Korlak J; Członkowski A; Członkowska A
    Eur J Neurol; 1999 May; 6(3):347-52. PubMed ID: 10210917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunostimulant RU41740 from Klebsiella pneumoniae activates human cells in whole blood to potentially stimulate innate and adaptive immune responses.
    Pedraza-Sánchez S; González-Hernández Y; Escobar-Gutiérrez A; Ramachandra L
    Int Immunopharmacol; 2006 Apr; 6(4):635-46. PubMed ID: 16504927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
    Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
    Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
    Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
    Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients.
    Weinstock-Guttman B; Hong J; Santos R; Tamaño-Blanco M; Badgett D; Patrick K; Baier M; Feichter J; Gallagher E; Garg N; Ramanathan M
    Mult Scler; 2006 Oct; 12(5):541-50. PubMed ID: 17086898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
    J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of interferon-beta 1a on the hypothalamic-pituitary-adrenal axis, leukocyte distribution and mood states in multiple sclerosis patients: results of a 1-year follow-up study.
    Goebel MU; Czolbe F; Becker H; Janssen OE; Schedlowski M; Limmroth V
    Eur Neurol; 2005; 53(4):182-7. PubMed ID: 15947464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.
    Genç K; Dona DL; Reder AT
    J Clin Invest; 1997 Jun; 99(11):2664-71. PubMed ID: 9169496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis.
    Ossege LM; Sindern E; Patzold T; Malin JP
    Int Immunopharmacol; 2001 Jun; 1(6):1085-100. PubMed ID: 11407304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killer-cell immunoglobulin-like receptor expression on lymphocyte subsets in multiple sclerosis patients treated with interferon-β: evaluation as biomarkers for clinical response.
    García-León JA; López-Gómez C; Orpez-Zafra T; Reyes-Garrido V; Marín-Bañasco C; Oliver-Martos B; Fernández O; Leyva L
    CNS Drugs; 2014 Jun; 28(6):559-70. PubMed ID: 24599774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy.
    Martínez-Rodríguez JE; Saez-Borderías A; Munteis E; Romo N; Roquer J; López-Botet M
    Clin Immunol; 2010 Oct; 137(1):41-50. PubMed ID: 20580616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis.
    Zang Y; Hong J; Robinson R; Li S; Rivera VM; Zhang JZ
    J Neuroimmunol; 2003 Apr; 137(1-2):144-53. PubMed ID: 12667659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.